AMSBIO announces that induced pluripotent stem (iPS) cell expert - Dr Masato Nakagawa from the Nobel Prize winning Yamanaka Lab** at the Centre for iPS Cell Research and Application, Kyoto University, Japan will give 3 talks in the UK on the 10th and 11th December 2018.
News
State of the discovery nation survey closing soon – still time to get your views heard!
Medicines Discovery Catapult is preparing our annual report for next year, which is based on the experience of companies in the sector – like you. We want to ensure your views are reflected.
Acquisition increases BioIVT’s supply of leukopaks, plasma and sera, and enhances its ability to support the in vitro diagnostic market
Wickham Laboratories will be exhibiting at Pharmig’s 26th annual conference held on the 28th & 29th November at the Belfry Hotel, Nottingham.
This year’s event will bring together an array of industry experts and regulators to discuss the latest research and findings within the pharmaceutical microbiology industry.
The conference programme will include the following topics among others:
Cambridge, UK., 30th October 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, continues to build a strong patent portfolio protecting the Company’s proprietary technology and product assets.
Cambridge, UK, 30 October 2018: TTP Ventus, manufacturer of the Disc Pump range of multi-award-winning micropumps, today introduced its XP Series, the latest pump products in the Company’s strategic development pipeline. The XP Series offers enhanced performance, efficiency, and a wide operational temperature range to support a more diverse range of applications across the medical, life sciences, environmental and defence sectors.
Cambridge, UK, 24 October 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has attracted an equity investment from Seventure Partners, a leading investor in the microbiome space. This new investment of £4m brings the total equity raised to date to £12m.
A brand-new lab facility is soon to be opening within the heart of Newcastle’s £350m urban development scheme - Newcastle Helix.
The Biosphere will provide a home for ambitious companies within life sciences and innovation, research and development. This is all part of the city’s wider commitment to support economic development and growth within the life sciences sector.